Spur Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Spur Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Spur Therapeutics: 6 sponsored US clinical trials, 1 recruiting.
Spur Therapeutics sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Haematologic Disease, with 1 trials.
Upper-quartile sponsor footprint
Spur Therapeutics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944
Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)
NCT06545136
A Gene Therapy Study in Patients With Gaucher Disease Type 1
NCT05324943
Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B
NCT05164471
AAV Gene Therapy Screening/Observational Protocol (ECLIPSE)
NCT04272554
A Fabry Disease Gene Therapy Study
NCT04040049
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Spur Therapeutics pipeline
1 recruiting of 6 indexed (17% open); 2 completed (33%).
Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Haematologic Disease (1 trial), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Spur Therapeutics: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Spur Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Spur Therapeutics page
6 registered trials is a research-attention snapshot, not an endorsement of Spur Therapeutics or any single study.
- 1 of Spur Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Haematologic Disease is the condition Spur Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Haematologic Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Spur Therapeutics pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.